Neurotech clinches key milestone: first shipment of improved autism devices
Neurotech International (ASX:NTI) has completed the first shipments of an improved version of its neurofeedback device, Mente Autism.
Pre-orders had been received from several of NTI’s distributors, and the devices are being delivered to Australia, Europe and the Middle East. Several distribution partners in these regions have begun marketing and information campaigns that will coincide with the release of the next batch of devices.
NTI is also preparing new marketing assets that can be used by distributors to promote Mente Autism in the local press and with key opinion leaders.
Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder (ASD). Designed for home use, it helps relax the minds of children on the spectrum, which in turn helps them to focus and engage positively with their environment.
The recently announced promising US clinical trial results provide NTI with important scientific evidence supporting the use of Mente Autism for children with ASD. As well as carrying significant weight with new and existing distributors of the device, the trial provides pivotal evidence to accompany the FDA submission for Mente Autism.
On top of this, NTI also expects to complete several multi-site studies that will further validate the product in different target markets. These studies are aimed at generating awareness and acceptance of the technology, in addition to supporting potential reimbursement.
To this end, NTI has recently appointed a consultant, Mediclever, to support applications for inclusion of Mente Autism on government reimbursement schemes in Australia. The costs of these projects will largely be borne by research institutions and their associated grant funding, with NTI donating research units and analytical support towards the studies.
As part of this process, NTI will also ship 20 research devices to academic partners in Italy and the Middle East, who have agreed to conduct studies in their respective regions, kicking off in September. Additional research agreements are currently being finalised.
As always, it should be noted that NTI is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
Neurotech CEO, Wolfgang Storf, commented: “We are pleased to commence shipping of the improved Mente Autism device to our distribution partners across Europe, Middle East and Australia. This is an important milestone following the US Clinical Trial and we look forward to fulfilling additional orders from our partners. We are ramping up production with a view to completing another shipment of devices in the coming weeks.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.